[go: up one dir, main page]

AR060869A1 - SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA - Google Patents

SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA

Info

Publication number
AR060869A1
AR060869A1 ARP070101988A ARP070101988A AR060869A1 AR 060869 A1 AR060869 A1 AR 060869A1 AR P070101988 A ARP070101988 A AR P070101988A AR P070101988 A ARP070101988 A AR P070101988A AR 060869 A1 AR060869 A1 AR 060869A1
Authority
AR
Argentina
Prior art keywords
gabapentin
refers
pharmaceutical composition
solid pharmaceutical
composition
Prior art date
Application number
ARP070101988A
Other languages
Spanish (es)
Original Assignee
Combino Pharm Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combino Pharm Sl filed Critical Combino Pharm Sl
Publication of AR060869A1 publication Critical patent/AR060869A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a una composicion farmacéutica solida que comprende gabapentina, un compuesto hidrofobico, un agente humectante, y un agente aglutinante. Dicha combinacion de excipientes confiere una buena estabilidad y buena biodisponibilidad del principio activo. También se refiere al uso de dicha composicion para la preparacion de formas farmacéuticas de gabapentina para su administracion por vía oral. Se refiere también a comprimidos preparados con dicha composicion que presentan unas propiedades apropiadas en cuanto a la solubilidad y a la biodisponibilidad de la gabapentina.This refers to a solid pharmaceutical composition comprising gabapentin, a hydrophobic compound, a wetting agent, and a binding agent. Said combination of excipients confers good stability and good bioavailability of the active substance. It also refers to the use of said composition for the preparation of pharmaceutical forms of gabapentin for oral administration. It also refers to tablets prepared with said composition that have appropriate properties in terms of solubility and bioavailability of gabapentin.

ARP070101988A 2006-05-08 2007-05-08 SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA AR060869A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200601164A ES2288117B1 (en) 2006-05-08 2006-05-08 SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA.

Publications (1)

Publication Number Publication Date
AR060869A1 true AR060869A1 (en) 2008-07-16

Family

ID=38668112

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101988A AR060869A1 (en) 2006-05-08 2007-05-08 SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA

Country Status (4)

Country Link
EP (1) EP2020993A2 (en)
AR (1) AR060869A1 (en)
ES (1) ES2288117B1 (en)
WO (1) WO2007128495A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009012788A1 (en) * 2009-03-13 2010-09-30 J. Rettenmaier & Söhne Gmbh + Co. Kg Compressible tablet material with oily agent, tablet and method and apparatus for their preparation
PT3277270T (en) 2015-04-01 2021-12-07 Akebia Therapeutics Inc COMPOSITIONS AND METHODS OF TREATMENT OF ANEMIA
US10342886B2 (en) 2016-01-26 2019-07-09 S.C. Johnson & Son, Inc. Extruded wax melt and method of producing same
US10010638B2 (en) 2016-06-14 2018-07-03 S. C. Johnson & Son, Inc. Wax melt with filler
WO2019036713A1 (en) 2017-08-18 2019-02-21 Abbvie Inc. Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome and adenomyosis
AU2018317472A1 (en) 2017-08-18 2020-03-05 Abbvie Inc. Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
GB2625579A (en) * 2022-12-21 2024-06-26 Novumgen Ltd An orally disintegrating tablet containing gabapentin or pharmaceutically acceptable salts thereof and the process of preparing the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076478A1 (en) * 1999-06-14 2000-12-21 Cosmo S.P.A. Controlled release and taste masking oral pharmaceutical compositions
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
ITMI20011337A1 (en) * 2001-06-26 2002-12-26 Farmatron Ltd ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF THE ACTIVE SUBSTANCE
EP1455751A1 (en) * 2001-12-20 2004-09-15 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
WO2003103634A1 (en) * 2002-06-07 2003-12-18 Ranbaxy Laboratories Limited Sustained release oral dosage forms of gabapentin
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
ES2288117A1 (en) 2007-12-16
WO2007128495A3 (en) 2008-05-02
WO2007128495A2 (en) 2007-11-15
ES2288117B1 (en) 2008-12-01
EP2020993A2 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
CL2009001766A1 (en) Solid pharmaceutical composition for oral administration comprising: a defined substantially amorphous taxane, a defined hydrophilic carrier and a defined surfactant; method of preparing the composition; and its use to treat neoplastic disease.
CR20110110A (en) PHARMACEUTICAL COMPOSITION
CU20080052A7 (en) SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF ACTIVE PRINCIPLE
AR060869A1 (en) SOLID PHARMACEUTICAL COMPOSITION OF GABAPENTINA
ITMI20041820A1 (en) COMPOSITION IN MICRO-PELLETS WITH CONTROLLED RELEASE OF PHYSIOLOGICALLY ACTIVE SUBSTANCES, PREPARATION PROCEDURE AND RELATED USE IN THE ZOOTECHNICAL SECTOR.
ECSP088239A (en) COMPOSITION OF SUSTAINED DRUG RELEASE
UY29410A1 (en) PHARMACEUTICAL COMPOSITIONS BASED ON METHODAMIDES OF ACID 4- (4 - / - 3 (-4-CHLORO-3-TRIFLUOROMETIFENIL) UREIDO) FENOXI) PIRIDIN-2-CARBOXYLIC, PREPARATION PROCEDURE AND APPLICATIONS.
CL2009002073A1 (en) Solid pharmaceutical composition for the controlled release of an active active agent in the gastrointestinal tract comprising at least one acidic agent with solubility of less than 0.3 mg / ml in aqueous solution at a ph around the pka of the acidic agent, a hydrophilic polymer , an achiever; Use in cardiovascular disorders.
CL2013001586A1 (en) Rapid dispersion microgranular composition comprising at least one sugar alcohol, a saccharide, or a mixture thereof, at least one super disintegrant and at least one multifunctional additive; oral disintegration tablet comprising the microgranular composition and at least one active ingredient; and manufacturing methods.
AR060755A1 (en) FORMULATIONS OF DIPEPTIDIL PEPTIDASA IV INHIBITORS (DPP IV)
EA200801275A1 (en) STABILIZED LANTAN CARBONATE COMPOSITIONS
AR061289A1 (en) STABILIZED PHARMACEUTICAL COMPOSITIONS THAT INCLUDE FESOTERODINE
CO6300932A2 (en) SOLID THERMOSTABLE COMPOSITION THAT INCLUDES IMPROVED SUBSTANCES OF PERMEABILITY FOR ACTIVE PHARMACEUTICAL INGREDIENTS OF DEFICIENT PERMEABILITY
CL2007002018A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED ISOXAZOLINS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND FOR THE TREATMENT OF A DISEASE CAUSED BY AN INCREASE IN THE CELL PROLIFERATION.
AR047928A1 (en) TETRAHYDROPIRIDOINDOL DERIVATIVES
CL2013003161A1 (en) Pharmaceutical composition in the form of rapidly dissolving microgranules for vaginal administration comprising a) a vaginally active drug, b) a polymeric excipient, c) a sugar alcohol, saccharide or a mixture thereof; preparation procedure
CO6400186A2 (en) ULIPRISTAL ACETATE TABLETS
DOP2010000331A (en) FORMULATION OF SOLID DRUG WITH DELAYED RELEASE
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2010021607A3 (en) Pharmaceutical formulation
PE20150773A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PHENYLEPHRINE
AR054238A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A BIGUANIDA AND A DERIVATIVE OF TIAZOLIDINDIONA
BR112015001640A2 (en) Formulations and production methods of formulations for use in colonic evacuation
UY29701A1 (en) LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
CO6280503A2 (en) NEURTURINE CONJUGATES NEW FOR PHARMACEUTICAL USE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal